Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. News
  7. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cellectis S A : and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

05/11/2021 | 04:38pm EDT

May 11, 2021 - Paris - Cellectis S.A. (NASDAQ: CLLS - Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells ('UCART') in the field of immuno-oncology, and Sanofi (Euronext: SAN - NYSE: SNY), today entered into a partnership agreement and a supply agreement regarding alemtuzumab, an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis sponsored UCART clinical trials.

Cellectis is the inventor of the combination of CD52 knockout UCART cells with a lymphodepleting regimen with an anti-CD52 antibody such as alemtuzumab. The CD52 knockout renders its UCART product candidates resistant to alemtuzumab as part of the lymphodepleting regimen. Patients' lymphodepleting regimens reduce host immune cells and should improve allogeneic CAR T-cell expansion and persistence. In Cellectis sponsored trials, alemtuzumab is currently used as part of the lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory ALL, and for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, but not for UCARTCS1 which has a self-lymphodepleting activity. Both Cellectis' UCART22 and UCART123 candidate products have the CD52 gene inactivated by TALEN® gene editing technology.

As part of the agreement, Sanofi will supply alemtuzumab to support Cellectis' clinical trials and the parties agreed to enter into discussions to execute a commercial supply of alemtuzumab under pre-agreed financial conditions.

Disclaimer

Cellectis SA published this content on 11 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2021 20:37:01 UTC.


© Publicnow 2021
All news about CELLECTIS S.A.
06/15CELLECTIS  : ' Innovation Days event highlighted New Product Development New Gen..
AQ
06/14CELLECTIS S A  : ' Innovation Days event highlighted New Product Development, Ne..
PU
06/14CELLECTIS S A  : ' Innovation Days event highlighted New Product Development,  N..
PU
06/14Cellectis' Innovation Days event highlighted New Product Development, New Gen..
GL
06/10CELLECTIS S A  : Corporate Presentation - June 2021
PU
06/07CELLECTIS S A  : Corporate Presentation - June 2021
PU
06/07ALLOGENE THERAPEUTICS  : Presents Positive Phase 1 Data on ALLO-501 and ALLO-501..
AQ
06/03European ADRs Move Lower in Thursday Trading
MT
06/03CELLECTIS  : S.A. Reports Results from Annual Shareholders' General Meeting Held..
AQ
06/02Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held..
GL
More news
Financials
Sales 2021 57,3 M 68,0 M 68,0 M
Net income 2021 -83,6 M -99,2 M -99,2 M
Net cash 2021 83,0 M 98,4 M 98,4 M
P/E ratio 2021 -5,53x
Yield 2021 -
Capitalization 583 M 691 M 692 M
EV / Sales 2021 8,72x
EV / Sales 2022 8,82x
Nbr of Employees 277
Free-Float 89,1%
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 22,25 €
Last Close Price 12,83 €
Spread / Highest target 87,1%
Spread / Average Target 73,4%
Spread / Lowest Target 59,8%
EPS Revisions
Managers and Directors
NameTitle
André Choulika Chief Executive Officer & Director
Eric Dutang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS S.A.-48.44%681
MODERNA, INC.93.81%81 297
LONZA GROUP AG15.68%53 313
IQVIA HOLDINGS INC.37.47%47 206
CELLTRION, INC.-24.79%32 426
SEAGEN INC.-10.75%27 835